세계의 종양용해성 바이러스 요법 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Oncolytic Virus Therapy was estimated to be worth US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

Oncolytic Virus Therapy is an innovative cancer treatment approach that employs genetically modified viruses to selectively infect and destroy tumor cells while activating the host's immune system to launch a systemic anti-tumor response. These viruses induce direct oncolysis and stimulate immunogenic cell death, positioning them as a pivotal class in immuno-oncology. Unlike chemotherapy or radiotherapy, this modality offers enhanced tumor selectivity, reduced toxicity, and strong synergistic potential when combined with immune checkpoint inhibitors. Products like Talimogene laherparepvec (T-VEC) have received FDA approval, showing promising efficacy in melanoma and drawing increasing R&D and commercial attention from global pharmaceutical companies.

With breakthroughs in immuno-oncology and the advancement of precision medicine, oncolytic virus therapy is entering a period of rapid growth. Global regulatory bodies are encouraging innovation through frameworks like the FDA's Breakthrough Therapy designation and the EU's PRIME program, facilitating clinical acceleration and early commercialization. The increasing incidence of cancer, particularly advanced solid tumors, underscores the unmet demand for novel mechanisms of action. Furthermore, leading biopharmaceutical companies are actively investing in M&A and strategic partnerships in this space, significantly expanding their pipelines. Since 2023, several oncolytic virus candidates have advanced into Phase III trials, marking a clear shift toward industrial scalability.

Despite promising prospects, several key challenges persist in the development of oncolytic virus therapies. Efficient in vivo delivery and tumor-specific targeting remain technical hurdles, especially in patients with immunosuppressive microenvironments or rapid viral clearance. Clinical trials are resource-intensive, requiring long timelines, significant funding, and multidisciplinary collaboration spanning virology, immunology, and translational medicine. Safety concerns also linger, including risks of off-target infection and systemic inflammation. Additionally, the industry still lacks a broad base of commercially successful precedents, leading to cautious investment sentiment and uncertain return on investment timelines.

The downstream demand for innovative cancer therapies is rapidly rising, with oncolytic viruses increasingly recognized as critical components of next-generation immunotherapy combinations. In difficult-to-treat tumors such as glioblastoma, pancreatic cancer, and bladder cancer, preliminary data indicates enhanced efficacy when combined with checkpoint inhibitors like PD-1/PD-L1. Clinical practitioners and patient communities alike are showing growing interest. Moreover, the Asia-Pacific region is emerging as a significant growth engine, with supportive policies and increasing clinical trial activity in countries like China, Japan, and South Korea, paving the way for future regional commercialization strategies.

This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncolytic Virus Therapy by region & country, by Type, and by Application.

The Oncolytic Virus Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Therapy.

Market Segmentation

By Company

• Amgen
• RIGVIR Group
• 3s-guojian
• Shuanghe Pharmaceutical

Segment by Type

• HSV-based Oncolytic Viruses
• Adenoviruses-based Oncolytic Viruses
• Vaccinia Virus-based Oncolytic Viruses
• Vesicular Stomatitis Virus-based Oncolytic Viruses
• Newcastle Disease Virus-based Oncolytic Viruses

Segment by Application

• Melanoma
• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oncolytic Virus Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Oncolytic Virus Therapy Product Introduction
• 1.2 Global Oncolytic Virus Therapy Market Size Forecast (2020-2031)
• 1.3 Oncolytic Virus Therapy Market Trends & Drivers
  • 1.3.1 Oncolytic Virus Therapy Industry Trends
  • 1.3.2 Oncolytic Virus Therapy Market Drivers & Opportunity
  • 1.3.3 Oncolytic Virus Therapy Market Challenges
  • 1.3.4 Oncolytic Virus Therapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Oncolytic Virus Therapy Players Revenue Ranking (2024)
• 2.2 Global Oncolytic Virus Therapy Revenue by Company (2020-2025)
• 2.3 Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Oncolytic Virus Therapy Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
• 2.6 Oncolytic Virus Therapy Market Competitive Analysis
  • 2.6.1 Oncolytic Virus Therapy Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Oncolytic Virus Therapy Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 HSV-based Oncolytic Viruses
  • 3.1.2 Adenoviruses-based Oncolytic Viruses
  • 3.1.3 Vaccinia Virus-based Oncolytic Viruses
  • 3.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
  • 3.1.5 Newcastle Disease Virus-based Oncolytic Viruses
• 3.2 Global Oncolytic Virus Therapy Sales Value by Type
  • 3.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Oncolytic Virus Therapy Sales Value, by Type (2020-2031)
  • 3.2.3 Global Oncolytic Virus Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Melanoma
  • 4.1.2 Prostate Cancer
  • 4.1.3 Breast Cancer
  • 4.1.4 Ovarian Cancer
  • 4.1.5 Others
• 4.2 Global Oncolytic Virus Therapy Sales Value by Application
  • 4.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Oncolytic Virus Therapy Sales Value, by Application (2020-2031)
  • 4.2.3 Global Oncolytic Virus Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Oncolytic Virus Therapy Sales Value by Region
  • 5.1.1 Global Oncolytic Virus Therapy Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Oncolytic Virus Therapy Sales Value by Region (2020-2025)
  • 5.1.3 Global Oncolytic Virus Therapy Sales Value by Region (2026-2031)
  • 5.1.4 Global Oncolytic Virus Therapy Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Oncolytic Virus Therapy Sales Value, 2020-2031
  • 5.2.2 North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
  • 5.3.2 Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Oncolytic Virus Therapy Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Oncolytic Virus Therapy Sales Value, 2020-2031
  • 5.5.2 South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Oncolytic Virus Therapy Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Oncolytic Virus Therapy Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.3.2 United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.4.2 Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.5.2 China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.6.2 Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.7.2 South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.9.2 India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Amgen
  • 7.1.1 Amgen Profile
  • 7.1.2 Amgen Main Business
  • 7.1.3 Amgen Oncolytic Virus Therapy Products, Services and Solutions
  • 7.1.4 Amgen Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Amgen Recent Developments
• 7.2 RIGVIR Group
  • 7.2.1 RIGVIR Group Profile
  • 7.2.2 RIGVIR Group Main Business
  • 7.2.3 RIGVIR Group Oncolytic Virus Therapy Products, Services and Solutions
  • 7.2.4 RIGVIR Group Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
  • 7.2.5 RIGVIR Group Recent Developments
• 7.3 3s-guojian
  • 7.3.1 3s-guojian Profile
  • 7.3.2 3s-guojian Main Business
  • 7.3.3 3s-guojian Oncolytic Virus Therapy Products, Services and Solutions
  • 7.3.4 3s-guojian Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
  • 7.3.5 3s-guojian Recent Developments
• 7.4 Shuanghe Pharmaceutical
  • 7.4.1 Shuanghe Pharmaceutical Profile
  • 7.4.2 Shuanghe Pharmaceutical Main Business
  • 7.4.3 Shuanghe Pharmaceutical Oncolytic Virus Therapy Products, Services and Solutions
  • 7.4.4 Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Shuanghe Pharmaceutical Recent Developments

8 Industry Chain Analysis

• 8.1 Oncolytic Virus Therapy Industrial Chain
• 8.2 Oncolytic Virus Therapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Oncolytic Virus Therapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Oncolytic Virus Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer